Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VG2062 in Advanced Solid Tumors
NCT07262164Phase 1Recruiting
- Sponsor
- Virogin Biotech
- Start
- Mar 2026
- Primary completion
- May 2027
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VG2062 in solid tumor (advanced stage), sponsored by Virogin Biotech. Primary endpoints: Adverse Events and Serious Adverse Events at 12 months and Maximum Tolerated Dose / Recommended Phase 2 Dose at 28 days. Started Mar 2026; status: recruiting.
02
Drugs
VG2062
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07262164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07262164.